Collegium Pharmaceutical (NASDAQ:COLL) Given Buy Rating at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Collegium Pharmaceutical (NASDAQ:COLL) in a research note released on Thursday morning,Benzinga reports. Needham & Company LLC currently has a $56.00 price target on the specialty pharmaceutical company’s stock, up from their previous price target of $54.00.

Other research analysts have also recently issued reports about the company. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Collegium Pharmaceutical in a research note on Friday. Zacks Research cut Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Barclays dropped their price objective on shares of Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating for the company in a report on Friday, January 9th. Truist Financial set a $58.00 target price on shares of Collegium Pharmaceutical in a research report on Tuesday, February 10th. Finally, Weiss Ratings cut shares of Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, March 5th. Four research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $53.40.

Collegium Pharmaceutical Stock Performance

NASDAQ:COLL opened at $36.30 on Thursday. The company has a quick ratio of 1.48, a current ratio of 1.57 and a debt-to-equity ratio of 2.59. The firm has a market capitalization of $1.15 billion, a PE ratio of 21.23 and a beta of 0.67. Collegium Pharmaceutical has a twelve month low of $23.23 and a twelve month high of $50.79. The stock’s 50-day simple moving average is $43.46 and its 200 day simple moving average is $41.90.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, missing analysts’ consensus estimates of $2.20 by ($0.16). The company had revenue of $205.45 million during the quarter, compared to analyst estimates of $206.36 million. Collegium Pharmaceutical had a net margin of 8.05% and a return on equity of 98.65%. The company’s revenue for the quarter was up 12.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.77 earnings per share. On average, analysts anticipate that Collegium Pharmaceutical will post 5.62 EPS for the current fiscal year.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 49,976 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $40.41, for a total transaction of $2,019,530.16. Following the completion of the transaction, the executive vice president owned 71,770 shares in the company, valued at approximately $2,900,225.70. This trade represents a 41.05% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 2.51% of the company’s stock.

Institutional Trading of Collegium Pharmaceutical

Large investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Collegium Pharmaceutical by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,046 shares of the specialty pharmaceutical company’s stock worth $569,000 after purchasing an additional 825 shares during the period. Millennium Management LLC boosted its holdings in shares of Collegium Pharmaceutical by 248.5% during the 1st quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company’s stock worth $19,338,000 after buying an additional 461,914 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Collegium Pharmaceutical by 7.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,014 shares of the specialty pharmaceutical company’s stock worth $2,120,000 after buying an additional 4,625 shares during the period. Jane Street Group LLC increased its stake in shares of Collegium Pharmaceutical by 218.7% in the 1st quarter. Jane Street Group LLC now owns 131,520 shares of the specialty pharmaceutical company’s stock valued at $3,926,000 after acquiring an additional 90,255 shares in the last quarter. Finally, Envestnet Asset Management Inc. lifted its position in shares of Collegium Pharmaceutical by 44.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 44,734 shares of the specialty pharmaceutical company’s stock valued at $1,323,000 after acquiring an additional 13,842 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.